Project description
Breakthrough magneto-plasmonic imaging technology
The EU-funded SWIMMOT project will establish the scientific and technological basis for radically new in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. The CA will be based on novel magnetic core/ plasmonic gold shell nanorods with engineered biofunctional shells. The magneto-plasmonic imaging will switch the CA on and off, resulting in complete removal of the imaging background. This discrimination of the background from the CA signal will yield ultra-high contrast molecular imaging. The technology will enable the in vivo visualisation and quantification of soluble biomarkers at cellular level resolution, surpassing all current capabilities. Developers plan to apply the technology to diabetes research and demonstrate its potential in the zebrafish model.
Objective
SWIMMOT will establish the scientific and technological basis for a radically new technique for in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. Our CA will be based on novel magnetic core / plasmonic gold shell nanorods with specifically engineered biofunctional shells. We will develop a new magneto-plasmonic imaging technique based on magnetic excitation and plasmonic signal generation to realise multimodal optical coherence tomography / photoacoustic imaging modes. The magneto-plasmonic imaging technique will turn our CA on and off, which will allow complete removal of the imaging background. This discrimination of the background from the CA signal will yield ultra-high contrast molecular imaging. In addition, SWIMMOT, for the first time, will enable in vivo quantification of soluble biomarker concentrations and visualisation down to cellular resolution, which holds the potential to revolutionise molecular imaging and to surpass all current technological paradigms.
These science and technology breakthroughs will enable detection of previously inaccessible in vivo physiology and molecular events, and elucidation of until now poorly understood biological mechanisms through studies in model organisms. This will in turn contribute to a better understanding of normal processes and disease pathogenesis. Thus, SWIMMOT will ultimately lead to earlier disease diagnostics for humans and to the development of new therapy concepts (including drugs). We will apply the SWIMMOT technology for diabetes research and will demonstrate its breakthrough potential for uncovering new biomolecular mechanisms in zebrafish model organisms.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1210 Wien
Austria